Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Laboratory data which differentiate meropenem and imipenem

J R Edwards1, P J Turner

  • 1Zeneca Pharmaceuticals, Macclesfield, Cheshire, UK.

Scandinavian Journal of Infectious Diseases. Supplementum
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma.

Nature communications·2024
Same author

Emergency treatment of peri-operative anaphylaxis: Resuscitation Council UK algorithm for anaesthetists.

Anaesthesia·2024
Same author

Image-Guided Transvaginal and Transabdominal Drain Placement for Surgical Navigation in a Patient with Tubo-Ovarian Abscess and Obstructed Hemivagina and Ipsilateral Renal Anomaly Syndrome.

Journal of pediatric and adolescent gynecology·2021
Same author

Pre-existing influenza-specific nasal IgA or nasal viral infection does not affect live attenuated influenza vaccine immunogenicity in children.

Clinical and experimental immunology·2020
Same author

Comment on 'Four-year data from use of the nut and soya allergy testing protocol before treatment with isotretinoin and alitretinoin'.

Clinical and experimental dermatology·2020
Same author

The risk of Kawasaki disease after pneumococcal conjugate & meningococcal B vaccine in England: A self-controlled case-series analysis.

Vaccine·2020
Same journal

Annual disease burden due to human papillomavirus 16 and 18 infections in Finland.

Scandinavian journal of infectious diseases. Supplementum·2009
Same journal

Annual disease burden due to human papillomavirus (HPV) 6 and 11 infections in Finland.

Scandinavian journal of infectious diseases. Supplementum·2009
Same journal

Supreme Court decision on genotypic tests for antiretroviral drugs resistance: Joint Criminal Divisions.

Scandinavian journal of infectious diseases. Supplementum·2004
Same journal

Brief summary of the legal proceeding.

Scandinavian journal of infectious diseases. Supplementum·2004
Same journal

Too early or too late: a never-ending dilemma with new technologies.

Scandinavian journal of infectious diseases. Supplementum·2004
Same journal

Genotypic resistance tests for the management of postexposure prophylaxis.

Scandinavian journal of infectious diseases. Supplementum·2004
See all related articles

Meropenem and imipenem are broad-spectrum carbapenem antibiotics. Meropenem shows enhanced activity against certain bacteria and potential for treating meningitis, unlike imipenem.

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Meropenem and imipenem are carbapenem antibiotics with broad antibacterial spectra and beta-lactamase stability.
  • Carbapenems differ in their activity against specific pathogens and their pharmacokinetic properties.

Purpose of the Study:

  • To compare the antibacterial spectrum, stability, and clinical potential of meropenem and imipenem.
  • To evaluate meropenem's efficacy in treating bacterial meningitis.

Main Methods:

  • In vitro susceptibility testing against various aerobic and anaerobic bacteria.
  • Assessment of stability to human renal dehydropeptidase-I (DHP-I).
  • Evaluation in a guinea-pig model of bacterial meningitis.

Related Experiment Videos

Main Results:

  • Both agents are active against most clinically important bacteria; meropenem shows greater potency against Pseudomonas aeruginosa, Pseudomonas cepacia, Haemophilus influenzae, Proteus, Morganella, and Providencia species.
  • Meropenem is stable to DHP-I and does not require co-administration with cilastatin.
  • Meropenem demonstrated potent activity against common meningeal pathogens in a guinea-pig meningitis model.

Conclusions:

  • Meropenem offers a distinct profile from imipenem, with potential advantages in treating specific infections, including bacterial meningitis.
  • Meropenem's stability to DHP-I and broad spectrum suggest its utility as a single-agent therapy.
  • Further clinical studies are needed to confirm the significance of observed differences in efficacy.